IXHL INCANNEX HEALTHCARE LTD

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.

Incannex Contact Information:

Incannex Healthcare Limited

Mr Joel Latham

Managing Director and Chief Executive Officer





Investor Relations Contact – United States

Alyssa Factor

Edison Group

+1 (860) 573 9637





EN
03/05/2023

Underlying

IXHLINCANNEX HEALTHCARE LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INCANNEX HEALTHCARE LTD

 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Announces Reverse Stock Split

Incannex Announces Reverse Stock Split Incannex’s common stock is expected to begin trading on a post-split adjusted basis on February 27, 2026 MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the...

February 25, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Announces Additional Appointments to Clinical Advi...

Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board Expands clinical expertise to support disciplined advancement of the PSX-001 program MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board (“CAB”): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent...

January 29, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Announces Formation of Clinical Advisory Board for...

Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program Strengthens clinical and regulatory guidance as PSX-001 advances to its next phase of development MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to ...

January 22, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Wins Research and Development Award for Obstructiv...

Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards MELBOURNE, Australia and NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced that it has been honored with the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, the Company’s oral fixed-dose combination product ...

January 15, 2026 1 EN
 PRESS RELEASE
Free
IXHL INCANNEX HEALTH...

Incannex Healthcare Delivers Transformational 2025 Progress and Outlin...

Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 Company enters 2026 with over $70 million in cash, two positive Phase 2 programs, FDA Fast Track Designation and runway well into 2027 MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, provides a 2025 corporate year-in-review and outlook for 2026, highlighting substantial clinical, regulatory and financial progress that positions the Company...

January 14, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch